Press Releases

 
Press Releases
Date Title and Summary View
May 15, 2018 SALT LAKE CITY, May 15, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today an...
May 8, 2018 Total Revenues of $193.5 Million GAAP Diluted EPS of $0.16 and Adjusted EPS of $0.31 Up 15 PercentCompany Raises Both Revenue and Adjusted EPS Guidance for Fiscal Year 2018Company Announces Commercial Coverage Decision for GeneSight...
May 7, 2018 SALT LAKE CITY, May 07, 2018 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that results from a large, well-controlled pharmacogenomics study in patients with major depressive disorder (MDD) were presented at the American Psychiatric Association annual meeti...
May 4, 2018 SALT LAKE CITY, May 04, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today an...
May 2, 2018 SALT LAKE CITY, May 02, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced tha...
Apr 27, 2018 SALT LAKE CITY, April 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at two upcoming investor conferences. On May 8, 2018, Mr. Capone will present at the 43rd annual Deuts...
Apr 27, 2018 SALT LAKE CITY, April 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, toda...
Apr 19, 2018 SALT LAKE CITY, April 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced the launch of its new Go Green sustainability initiative. As part of the initiative, Myriad is initially focused on promoting increased recycling and reducing material waste used throughout ...
Apr 17, 2018 SALT LAKE CITY, April 17, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal third-quarter 2018 sales and earnings conference call with investors and analysts at 7:30 a.m. ET on Tuesday, May 8, 2018.  During the call, Mark C. ...
Apr 2, 2018 SALT LAKE CITY, April 02, 2018 (GLOBE NEWSWIRE) -- Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), announced today that the Japanese Ministry of Health, Labour, and Welfare has granted manufacturing and marketing approval for Myriad's BRACAnalysis®...
Page:
1
... NextLast
= add release to Briefcase